[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

@YHdjdhd YHsudhd Hdjdhd

YHsudhd Hdjdhd posts on X about $bmy, $bntx, $mgx, remarkable the most. They currently have XX followers and X posts still getting attention that total XXX engagements in the last XX hours.

Engagements: XXX #

• X Week XXXXX +29%
• X Month XXXXX -XXX%
• X Months XXXXXXXXXX +43,532%
• X Year XXXXXXXXXX +473,362%

Mentions: X #

• X Week X +33%
• X Month XX -XX%
• X Months XX +880%
• X Year XX +179%

Followers: XX #

• X Week XX +8.70%
• X Month XX +6.40%
• X Months XX +39%
• X Year XX +285%

CreatorRank: XXXXXXXXX #

Social Influence

Social category influence stocks XX%

Social topic influence $bmy #6, $bntx #1, $mgx 12.5%, remarkable 12.5%, global XXXX%

Top accounts mentioned or mentioned by @rnaianalyst @adamfeuerstein @auditor112017 @michaelmaiello @mortysoley @geneinvesting @alexfabra339670 @3primeanalytica @a_may_md

Top assets mentioned Bristol-Myers Squibb Co (BMY)

Top Social Posts

Top posts by engagements in the last XX hours

"@RNAiAnalyst Does this news shift your take on $mgx"
X Link 2025-12-01T18:51Z XX followers, XXX engagements

"New global Phase X data for pumitamig in TNBC look even stronger in detail: 1) PD-L1-negative pts respond almost as well as PD-L1-positive (uORR XXXX% vs 70.6%) a huge unmet need. 2) ctDNA clearance is remarkable (median XXX% at C3D1; XX% at XX mg/kg) $BNTX $BMY"
X Link 2025-12-09T13:35Z XX followers, XXX engagements

"Key new insights from the ROSETTA Breast-01 Phase X design: X The trial focuses on PD-L1-negative TNBC a population with no effective IO standard and major commercial upside. X Dual primary endpoints (OS + PFS by BICR) in a 558-pt double-blind global trial $BNTX $BMY"
X Link 2025-12-09T13:38Z XX followers, XXX engagements